Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Rafael holdings, inc. save search
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
Published: 2023-01-30 (Crawled : 15:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 0.0%
H: 2.46%
C: -1.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
TARA | $2.81 -6.33% -6.76% 420K
|
Health Technology
|
| O: 1.27%
H: 1.61%
C: 0.02%
therapeutics financial
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase
Published: 2022-01-06 (Crawled : 21:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 5.98%
H: 0.4%
C: -2.62%
als ces 613
Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell SarcomaNew Trial Sites Open at Cleveland Clinic Children’s and University of Michigan
Published: 2021-11-11 (Crawled : 15:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 0.29%
H: 5.17%
C: 0.58%
phase 1 cpi-613 children trial enroll
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published: 2021-10-28 (Crawled : 14:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: -78.09%
H: 36.16%
C: 22.39%
myeloid leukemia cancer leukemia phase 3 trial pancreatic cpi-613 pancreas acute myeloid leukemia
Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer
Published: 2021-10-06 (Crawled : 11:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 10.29%
H: 4.57%
C: -3.81%
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: -6.41%
H: 3.17%
C: 1.81%
trial cpi-613 enroll
Rafael Holdings Announces $104.2 Million Private Placement
Published: 2021-08-20 (Crawled : 12:15) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: -8.82%
H: 6.35%
C: -4.74%
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda potential test therapy cancer gastrointestinal drug cpi-613 milestone designation
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company
Published: 2021-06-21 (Crawled : 11:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 2.69%
H: 2.44%
C: -0.98%
merge
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.